1. Home
  2. LIXT vs ENLV Comparison

LIXT vs ENLV Comparison

Compare LIXT & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lixte Biotechnology Holdings Inc.

LIXT

Lixte Biotechnology Holdings Inc.

HOLD

Current Price

$3.99

Market Cap

25.4M

Sector

Health Care

ML Signal

HOLD

Logo Enlivex Therapeutics Ltd.

ENLV

Enlivex Therapeutics Ltd.

HOLD

Current Price

$0.83

Market Cap

26.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LIXT
ENLV
Founded
2005
2005
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.4M
26.6M
IPO Year
N/A
1995

Fundamental Metrics

Financial Performance
Metric
LIXT
ENLV
Price
$3.99
$0.83
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$7.00
AVG Volume (30 Days)
90.8K
11.5M
Earning Date
11-12-2025
11-28-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.64
$0.83
52 Week High
$6.26
$2.10

Technical Indicators

Market Signals
Indicator
LIXT
ENLV
Relative Strength Index (RSI) 42.98 36.94
Support Level $4.01 $0.89
Resistance Level $4.40 $1.25
Average True Range (ATR) 0.31 0.11
MACD -0.01 -0.02
Stochastic Oscillator 22.34 8.09

Price Performance

Historical Comparison
LIXT
ENLV

About LIXT Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

About ENLV Enlivex Therapeutics Ltd.

Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.

Share on Social Networks: